Jeremy Bender, Day One Biopharmaceuticals CEO
June 18, 2024 10:45 AM EDT
Deals
China

Day One en­ters ADC field, go­ing af­ter a tar­get that once at­tract­ed Ab­b­Vie and now Gen­mab

Kyle LaHucik

Senior Reporter

Short­ly af­ter se­cur­ing its first FDA ap­proval and bag­ging $108 mil­lion from a pri­or­i­ty re­view vouch­er sale, Day One …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

The End­points 11 win­ners: Big bets on AI, new fron­tiers in edit­ing, a neu­ro re­nais­sance and Chi­nese chem­istry

No­vo Nordisk to de­crease some in­sulin pen man­u­fac­tur­ing, tran­si­tion sup­ply

Cas­sa­va and its for­mer ex­ecs set­tle SEC charges for ‘mis­lead­ing’ Alzheimer’s drug da­ta

Ex­clu­sive: J&J folds car­dio­vas­cu­lar and meta­bol­ic drug unit

FDA ap­proves Dupix­ent in COPD, open­ing ‘next chap­ter’ for Sanofi and Re­gen­eron’s best­seller

sponsored

PD­Cs vs. AD­Cs: A New Fron­tier in Tar­get­ed Can­cer Ther­a­pies and the Po­ten­tial for De­vel­op­ment Part­ner­ships

A service from the Financial Times